Cleveland Story

CBLI -- USA Stock

USD 5.74 0.08 1.37%

Macroaxis Story

Cleveland Biolabs Invested Capital is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital was reported at 66,992. The current Market Capitalization is estimated to increase to about 46.8 M, while Net Income Per Employee is projected to decrease to (103 K). The basic intention for this outlook is to give stockholders our perspective on Cleveland for May. We will forecast Cleveland Biolabs value for stockholders.

Published over a week ago

View all stories for Cleveland Biolabs | View All Stories

Is Cleveland Biolabs (NASDAQ:CBLI) outlook positive for May 2021?

Cleveland Biolabs holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.7166, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Cleveland's beta means in this case. As returns on the market increase, returns on owning Cleveland Biolabs are expected to decrease at a much lower rate. During the bear market, Cleveland Biolabs is likely to outperform the market. Although it is vital to follow Cleveland Biolabs historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. Our philosophy in foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Cleveland Biolabs expected return of 1.17 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use Cleveland Biolabs jensen alpha, and the relationship between the coefficient of variation and potential upside to analyze future returns on Cleveland Biolabs.

There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Cleveland Biolabs. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Cleveland Biolabs

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Cleveland Biolabs' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Cleveland Biolabs in the context of predictive analytics.

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Cleveland Biolabs. Your research has to be compared to or analyzed against Cleveland Biolabs' peers to derive any actionable benefits. When done correctly, Cleveland Biolabs' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Cleveland Biolabs.

How important is Cleveland Biolabs's Liquidity

Cleveland Biolabs financial leverage refers to using borrowed capital as a funding source to finance Cleveland Biolabs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cleveland Biolabs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cleveland Biolabs's total debt and its cash.

How Cleveland utilizes its cash?

To perform a cash flow analysis of Cleveland Biolabs, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cleveland Biolabs is receiving and how much cash it distributes out in a given period. The Cleveland Biolabs cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Cleveland Biolabs Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (2.37 Million)

Cleveland Biolabs exotic insider transaction detected

Legal trades by Cleveland Biolabs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Cleveland insider trading alert for general transaction of common stock par value $0.005 per share by James Antal, the corporate stakeholder, on 19th of March 2021. This event was filed by Cleveland Biolabs Inc with SEC on 2013-03-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Cleveland Biolabs

The current price rise of Cleveland Biolabs could raise concerns from stockholders as the firm it trading at a share price of 6.16 on very low momentum in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in May. The stock standard deviation of daily returns for 30 days investing horizon is currently 7.43. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cleveland Biolabs partners.

Returns Breakdown

	Return on Investment	(70.89)
	Return on Assets	(0.9)
	Return on Equity	0.93
	Return Capital	34.1
	Return on Sales	(9.36)

Another 3 percent rise for Cleveland Biolabs

Standard deviation is down to 7.36. It may hint to a possible volatility drop.

As of the 3rd of April, Cleveland Biolabs shows the risk adjusted performance of 0.1264, and Mean Deviation of 5.34. Cleveland Biolabs technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Cleveland Biolabs, which can be compared to its rivals. Please confirm Cleveland Biolabs jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Cleveland Biolabs is priced correctly, providing market reflects its regular price of 6.16 per share. Given that Cleveland Biolabs has jensen alpha of 1.13, we suggest you to validate Cleveland Biolabs's prevailing market performance to make sure the company can sustain itself at a future point.

Our Final Takeaway

While some other firms under the biotechnology industry are still a bit expensive, Cleveland Biolabs may offer a potential longer-term growth to stockholders. To sum up, as of the 3rd of April 2021, we believe Cleveland Biolabs is currently overvalued. It moves indifferently to market moves and projects high odds of financial distress in the next two years. Our overall 30 days buy-or-sell advice on the company is Strong Sell.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Cleveland Biolabs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC